
According to data from Benzinga Pro, during Q1, Exact Sciences's (NASDAQ:EXAS) reported sales totaled $486.57 million. Despite a 17.98% increase in earnings, the company posted a loss of $180.94 million. Exact Sciences collected $473.81 million in revenue during Q4, but reported earnings showed a $220.61 million loss.